CMS significantly reduced its projected savings for the GLOBE Model in the final rule. While the model is expected to generate $440 million in Medicare Part B savings, the estimated impact on beneficiary premiums is only about four cents per month.
Biopharma companies are facing overlapping policy changes across pricing, reimbursement, 340B, PBM reform, and Medicare drug negotiation. Explore the key developments shaping product, portfolio, and market access decisions heading into 2027.
AI in market access can help biopharma teams apply payer intelligence earlier and more consistently across evidence, pricing, launch, and access strategy.
Access is now shaping commercial performance. Learn how policy, payer dynamics, and evidence are redefining access strategy and what it requires from organizations today.
A data-driven approach to patient support services modeling that helps manufacturers forecast demand, evaluate program design, and manage affordability, access, and cost with confidence.
Market access ecosystem mapping helps biopharma teams move from identifying stakeholders to understanding how influence operates across the access landscape, enabling more coordinated engagement, stronger alignment, and more informed decision-making.
The 2026 Medicare Part D redesign lowers some drug prices but shifts cost sharing. Coinsurance and higher deductibles may increase out-of-pocket costs for many beneficiaries.
Regulatory approval does not guarantee payer coverage. As reimbursement decisions increasingly depend on comparative value, budget impact, and real-world evidence, integrating HEOR and payer considerations into clinical trial design can help biopharma teams anticipate access challenges and support stronger reimbursement discussions at launch.
Market access is increasingly shaping biopharma decisions earlier in the lifecycle. This article explores how policy uncertainty, evidence expectations, and access strategy are influencing development, investment, and long-term value realization.
Magnolia Market Access examines the factors shaping access to chimeric antigen receptor T-cell (CAR-T) therapies in the Medicare fee-for-service population.